Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
10.14
Dollar change
+0.07
Percentage change
0.70
%
Index- P/E- EPS (ttm)- Insider Own57.15% Shs Outstand47.61M Perf Week33.42%
Market Cap482.77M Forward P/E- EPS next Y-1.89 Insider Trans5.70% Shs Float20.40M Perf Month-
Income- PEG- EPS next Q-0.33 Inst Own- Short Float5.04% Perf Quarter-
Sales- P/S- EPS this Y89.18% Inst Trans- Short Ratio1.74 Perf Half Y-
Book/sh-6.45 P/B- EPS next Y2.33% ROA- Short Interest1.03M Perf Year-
Cash/sh0.94 P/C10.77 EPS next 5Y- ROE- 52W Range6.91 - 14.50 Perf YTD-21.09%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-30.07% Beta-
Dividend TTM- Quick Ratio5.57 Sales past 5Y0.00% Gross Margin- 52W Low46.64% ATR (14)1.30
Dividend Ex-Date- Current Ratio5.57 EPS Y/Y TTM- Oper. Margin- RSI (14)- Volatility15.71% -
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price22.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-49.49% Payout- Rel Volume0.78 Prev Close10.07
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume591.92K Price10.14
SMA2010.73% SMA5010.73% SMA20010.73% Trades Volume461,641 Change0.70%
Date Action Analyst Rating Change Price Target Change
Feb-28-24Initiated Evercore ISI Outperform
Feb-27-24Initiated Morgan Stanley Overweight $18
Feb-27-24Initiated BofA Securities Buy $26
Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with better solutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers. Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elia MarcDirectorFeb 06Buy15.00466,6666,999,9901,856,117Feb 08 04:32 PM
CVF, LLC10% OwnerFeb 06Buy15.00333,3334,999,9954,673,870Feb 06 08:39 PM
Royan AjayDirectorFeb 06Buy15.00333,3334,999,9951,251,900Feb 08 04:37 PM
Mithril LP10% OwnerFeb 06Buy15.00333,3334,999,9951,251,900Feb 08 04:35 PM